We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.85 | 0.80 | 0.90 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.49 | 1.54M |
From Apr 2021 to Apr 2024
TIDMN4P
RNS Number : 6200C
N4 Pharma PLC
24 February 2022
24 February 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Notice of Annual General Meeting
and
Posting of Annual Report and Accounts
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website
www.n4pharma.com and will be posted to shareholders today.
The AGM will be held at 11.00am on 24 March 2022 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
N4 Pharma Plc Via IFC Advisory Nigel Theobald, CEO Luke Cairns, Executive Director SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470 Nominated Adviser and Joint Broker 0470 Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657 Joint Broker 0050 Andy Thacker IFC Advisory Limited Tel: +44 (0)20 3934 Financial PR 6630 Graham Herring Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCSEUFMDEESEIE
(END) Dow Jones Newswires
February 24, 2022 02:00 ET (07:00 GMT)
1 Year N4 Pharma Chart |
1 Month N4 Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
